{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:20:27Z","timestamp":1758810027001},"reference-count":35,"publisher":"Japan Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1507\/endocrj.ej20-0173","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T22:07:50Z","timestamp":1597874870000},"page":"103-110","source":"Crossref","is-referenced-by-count":2,"title":["Acromegaly accompanied by diabetes mellitus and polycystic kidney disease"],"prefix":"10.1507","volume":"68","author":[{"given":"Daisuke","family":"Otani","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan"},{"name":"Department of Diabetes and Endocrinology, Shiga General Hospital, Moriyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan"},{"name":"Department of Diabetes and Endocrinology, Shiga General Hospital, Moriyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Hojo","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Shiga General Hospital, Moriyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Nakae","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Shiga General Hospital, Moriyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Moriyoshi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Yasoda","sequence":"additional","affiliation":[{"name":"Clinical Research Center, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Usui","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisato","family":"Tatsuoka","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuya","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taizou","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Shiga General Hospital, Moriyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355: 2558\u20132573.","DOI":"10.1056\/NEJMra062453"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119: 3189\u20133202.","DOI":"10.1172\/JCI39375"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Gadelha MR, Kasuki L, Lim DST, Fleseriu M (2019) Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev 40: 268\u2013332.","DOI":"10.1210\/er.2018-00115"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Wilson PD (2004) Polycystic kidney diseases. N Engl J Med 350: 151\u2013162.","DOI":"10.1056\/NEJMra022161"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Horie S, Mochizuki T, Muto S, Hanaoka K, Fukushima Y, et al. (2016) Evidence-based clinical practice guidelines for polycystic kidney disease 2014. Clin Exp Nephrol 20: 493\u2013509.","DOI":"10.1007\/s10157-015-1219-7"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Pei Y (2006) Diagnostic approach in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 1: 1108\u20131114.","DOI":"10.2215\/CJN.02190606"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Tokiwa S, Muto S, China T, Horie S (2011) The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol 15: 539\u2013545.","DOI":"10.1007\/s10157-011-0428-y"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Fajfr R, M\u00fcller B, Diem P (2002) Hypophyseal incidentaloma in a patient with autosomal dominant polycystic kidney disease. Praxis (Bern 1994) 91: 1123\u20131126 (In German).","DOI":"10.1024\/0369-8394.91.25.1123"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, et al. (2005) Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 68: 206\u2013216.","DOI":"10.1111\/j.1523-1755.2005.00395.x"},{"key":"10","unstructured":"10 Kannabiran M, Singh V, Grewal S (2006) Acromegaly presenting as psychotic disorder in a family with familial autosomal dominant polycystic kidney disease. Ger J Psychiatry 9: 136\u2013138."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Syro LV, Sundsbak JL, Scheithauer BW, Toledo RA, Camargo M, et al. (2012) Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation. Pituitary 15: 342\u2013349.","DOI":"10.1007\/s11102-011-0325-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Mangaraj S, Patro D, Choudhury AK, Baliarsinha AK (2019) A rare case of acromegaly and autosomal dominant polycystic kidney disease: case report and brief review of literature. AACE Clin Case Rep 5: e302\u2013e306.","DOI":"10.4158\/ACCR-2019-0128"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 The hypothalamic-pituitary dysfunction study group of the Ministry of Health Labour and Welfare (2019) Diagnosis and treatment of hypothalamic pituitary dysfunction. Nihon Naibunpi Gakkai Zasshi 95 Suppl: 1\u201360 (In Japanese).","DOI":"10.1507\/endocrine.95.S.May_1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Nishio S, Fujiwara S, Morioka T, Fukui M (1995) Rathke\u2019s cleft cysts within a growth hormone producing pituitary adenoma. Br J Neurosurg 9: 51\u201355.","DOI":"10.1080\/02688699550041755"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15 Heck A, Emblem KE, Casar-Borota O, Bollerslev J, Ringstad G (2016) Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine 52: 333\u2013343.","DOI":"10.1007\/s12020-015-0766-8"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Akirov A, Asa SL, Amer L, Shimon I, Ezzat S (2019) The clinicopathological spectrum of acromegaly. J Clin Med 8: 1962.","DOI":"10.3390\/jcm8111962"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17 Flyvbjerg A (2000) Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 43: 1205\u20131223.","DOI":"10.1007\/s001250051515"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Vasylyeva TL, Ferry RJ Jr (2007) Novel roles of the IGF-IGFBP axis in etiopathophysiology of diabetic nephropathy. Diabetes Res Clin Pract 76: 177\u2013186.","DOI":"10.1016\/j.diabres.2006.09.012"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Feld SM, Hirschberg R, Artishevsky A, Nast C, Adler SG (1995) Insulin-like growth factor I induces mesangial proliferation and increases mRNA and secretion of collagen. Kidney Int 48: 45\u201351.","DOI":"10.1038\/ki.1995.265"},{"key":"20","unstructured":"20 Yang S, Chintapalli J, Sodagum L, Baskin S, Malhotra A, et al. (2005) Activated IGF-1R inhibits hyperglycemia-induced DNA damage and promotes DNA repair by homologous recombination. Am J Physiol Renal Physiol 289: F1144\u2013F1152."},{"key":"21","unstructured":"21 Baud L, Fouqueray B, Bellocq A, Doublier S, Dumoulin A (1999) Growth hormone and somatostatin in glomerular injury. J Nephrol 12: 18\u201323."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Reddy GR, Pushpanathan MJ, Ransom RF, Holzman LB, Brosius FC, et al. (2007) Identification of the glomerular podocyte as a target for growth hormone action. Endocrinology 148: 2045\u20132055.","DOI":"10.1210\/en.2006-1285"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, et al. (1997) Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99: 342\u2013348.","DOI":"10.1172\/JCI119163"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Kumar PA, Kotlyarevska K, Dejkhmaron P, Reddy GR, Lu C, et al. (2010) Growth hormone (GH)-dependent expression of a natural antisense transcript induces zinc finger E-box-binding homeobox 2 (ZEB2) in the glomerular podocyte: a novel action of GH with implications for the pathogenesis of diabetic nephropathy. J Biol Chem 285: 31148\u201331156.","DOI":"10.1074\/jbc.M110.132332"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Kamenick\u00fd P, Mazziotti G, Lomb\u00e8s M, Giustina A, Chanson P, et al. (2014) Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev 35: 234\u2013281.","DOI":"10.1210\/er.2013-1071"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Wanke R, Hermanns W, Folger S, Wolf E, Brem G (1991) Accelerated growth and visceral lesions in transgenic mice expressing foreign genes of the growth hormone family: an overview. Pediatr Nephrol 5: 513\u2013521.","DOI":"10.1007\/BF01453693"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Nakamura T, Ebihara I, Nagaoka I, Tomino Y, Nagao S, et al. (1993) Growth factor gene expression in kidney of murine polycystic kidney disease. J Am Soc Nephrol 3: 1378\u20131386.","DOI":"10.1681\/ASN.V371378"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Aukema HM, Housini I (2001) Dietary soy protein effects on disease and IGF-I in male and female Han: SPRD-cy rats. Kidney Int 59: 52\u201361.","DOI":"10.1046\/j.1523-1755.2001.00465.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Parker E, Newby LJ, Sharpe CC, Rossetti S, Streets AJ, et al. (2007) Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras\/Raf signalling system. Kidney Int 72: 157\u2013165.","DOI":"10.1038\/sj.ki.5002229"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Fragiadaki M, Lannoy M, Themanns M, Maurer B, Leonhard WN, et al. (2017) STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease. Kidney Int 91: 575\u2013586.","DOI":"10.1016\/j.kint.2016.10.039"},{"key":"31","unstructured":"31 Liu M, Xu YF, Feng Y, Zhai W, Che JP, et al. (2013) Androgen-STAT3 activation may contribute to gender disparity in human simply renal cysts. Int J Clin Exp Pathol 6: 686\u2013694."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Yamamoto M, Matsumoto R, Fukuoka H, Iguchi G, Takahashi M, et al. (2016) Prevalence of simple renal cysts in acromegaly. Intern Med 55: 1685\u20131690.","DOI":"10.2169\/internalmedicine.55.6560"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, et al. (2015) Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 26: 160\u2013172.","DOI":"10.1681\/ASN.2013101138"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, et al. (2017) Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 377: 1930\u20131942.","DOI":"10.1056\/NEJMoa1710030"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Oguro M, Kogure Y, Hoshino J, Ubara Y, Mizuno H, et al. (2018) Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease. J Nephrol 31: 961\u2013966.","DOI":"10.1007\/s40620-018-0545-8"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/68\/1\/68_EJ20-0173\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T23:12:23Z","timestamp":1667949143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/68\/1\/68_EJ20-0173\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej20-0173","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}